MetaCap

Lakefront Biotherapeutics (LKFT) vs Pharvaris N.V. (PHVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pharvaris N.V. (PHVS) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 26.0% versus a gain of 8.6%. Over five years, PHVS leads with a +131.3% price change compared with -31.8% for LKFT. Pharvaris N.V. is the larger company by market cap ($2.21 billion vs $2.18 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LKFT+8.64%PHVS+25.98%
+60%+21%-19%
Nov 21, 20251 yearNov 20, 2026
LKFT-35.27%PHVS+100.90%
+156%+28%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LKFT versus PHVS key metrics
MetricLKFTPHVS
Share price$33.31$31.28
Market cap$2.18B$2.21B
1-day change-0.24%-1.20%
YTD return+1.87%+12.72%
1-year return+8.64%+25.98%
5-year return-31.80%+131.28%
P/E ratio (TTM)2.39—
EPS (TTM)$13.94$-3.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-25.99M
52-week high$36.24$43.25
52-week low$25.68$23.15
Distance from 52-week high-8.08%-27.68%
Analyst consensusholdstrong_buy
Avg. price target upside-7.39%+86.29%
Average volume280.49K756.20K
Shares outstanding65.48M70.79M
Employees196168
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHVS has outperformed LKFT by 17.3 percentage points over the past year.

About Lakefront Biotherapeutics

LKFT stock →

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees

About Pharvaris N.V.

PHVS stock →

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.

Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees

LKFT vs PHVS FAQ

Which is bigger, Lakefront Biotherapeutics or Pharvaris N.V.?

Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.21B compared with $2.18B for Lakefront Biotherapeutics (LKFT).

Which stock has performed better over the past year, LKFT or PHVS?

PHVS returned +25.98% over the past 12 months, compared with +8.64% for LKFT (price return, excluding dividends). Past performance does not predict future results.

Are Lakefront Biotherapeutics and Pharvaris N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons